Thus, animal models of CPVT (both gain-of-function RyR2 and loss-of-function Casq2) have been used to investigate arrhythmogenic mechanisms and screen therapeutic modalities315. This evidence concerns the gene CASQ2 and catecholaminergic polymorphic ventricular tachycardia.